Профилактика и лечение умеренных когнитивных нарушений

1. Гаврилова С.И., Селезнева Н.Д., Густов А.В. и др. Возможности превентивной терапии болезни Альцгеймера: результаты 3-летнего проспективного открытого сравнительного исследования эффективности и безопасности курсовой терапии церебролизином и кавинтоном у пожилых пациентов с синдромом мягкого когнитивного снижения. Журн. неврол. и психиатр. 2010; 110 (1): 62–9.
2. Емелин А.Ю. Новые критерии диагностики болезни Альц­геймера. Неврология. Нейропсихиатрия. Психосоматика. 2011; 4: 5–8.
3. Емелин А.Ю., Одинак М.М., Труфанов Г.Е. и др. Возможности позитронной эмиссионной томографии в дифференциальной диагностике деменций. Вестн. рос. воен.-мед. акад. 2010; 4 (32): 46–51.
4. Захаров В.В. Умеренные когнитивные расстройства. Диагностика и лечение. Рус. мед. журн. 2006; 14 (9): 685–8.
5. Иванова Г.Е., Петрова Е.А., Скворцова В.И. Ранняя реабилитация больных церебральным инсультом. Врач. 2007; 9: 4–8.
6. Яхно Н.Н., Захаров В.В., Локшина Ф.Б. и др. Танакан (EGb 761) в терапии умеренных когнитивных нарушений (мультицентровое исследование). Журн. неврол. и психиатр. 2006; 12: 48–53.
7. Balk E, Raman G, Tatsioni A et al. Vitamin B6, B12, and folic acid supplementation and cognitive function: a systematic review of randomized trials. Arch Intern Med 2007; 167 (1): 21–30.
8. Barberger-Gateau P, Raffaitin C, Letenneur L et al. Dietary patterns and risk of dementia: the Three-City cohort study. Neurology 2007; 69: 1921–30.
9. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6 (3): 131–44.
10. Chapman N, Huxley R, Anderson C et al. Effects of a Perindopril-Based Blood Pressure-Lowering Regimen on the Risk of Recurrent Stroke According to Stroke Subtype and Medical History. The PROGRESS Trial. Stroke 2004; 35: 116.
11. Chittaranjan Andrade and Rajiv Radhakrishnan. The prevention and treatment of cognitive decline and dementia: An overview of recent research on experimental treatments. Indian J Psychiatry 2009; 51 (1): 12–25.
12. Cramer C, Haan M, Galea S et al. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008; 71: 344–50.
13. Colciaghia F, Borronib B, Zimmermanna M et al. Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. Neurobiol Dis 2004; 16: 454–60.
14. Collins R, Armitage J, Parish S et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757–67.
15. De Kosky S. A randomized double-blind, placebo-controlled trial to evaluate the efficacy and safety of galantamine in subjects with mild cognitive impairment (MCI) clinically at risk for development of clinically probable Alzheimer's disease. Protocol No. GAL–INT–11. 2004.
16. De Kosky S, Williamson J, Fitzpatrick A et al. Ginkgo biloba for prevention of dementia. JAMA 2008; 300: 2253–62.
17. Diniz B, Pinto J, Gonzaga M et al. Treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 2009; 259 (4): 248–56.
18. Dunn N, Holmes C, Mullee M. Does lithium therapy protect against the onset of dementia? Alzheimer Dis Assoc Disord 2005; 19: 20–2.
19. Etgen T, Sander D, Bickel H. Mild Cognitive Impairment and Dementia. The Importance of Modifiable Risk Factors. Dtsch Arztebl Int 2011; 108 (44): 743–50.
20. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev 2005; 2: CD000269.
21. Feldman H, Ferris S, Winblad B et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007; 6 (6): 501–12.
22. Forette F, Seux ML, Staessen J et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347–51.
23. Heyn P, Abreu B, Ottenbacher K. The effects of exercise training on elderly persons with cognitive impairment and dementia: a meta-analysis. Arch Phys Med Rehabil 2004; 85: 1694–704.
24. Grady D, Yaffe K, Kristof M et al. Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/ progestin Replacement Study. Am J Med 2002; 113 (7): 543–8.
25. Griffin W. Perispinal etanercept: Potential as an Alzheimer therapeutic. J Neuroinflammation 2008; 5: 1–3.
26. Kramer A, Bherer L, Colcombe S et al. Environmental influences on cognitive and brain plasticity during aging. J Gerontol A Biol Sci Med Sci 2004; 59 (M): 940–57.
27. Kessing L, Søndergård, Forman J. Andersen P. Lithium treatment and risk of dementia. Arch Gen Psychiatry 2008; 65: 1331–5.
28. Lannfelt L, Blennow K, Zetterberg H et al. Safety, efficacy, and biomarker findings of PBT2 in targeting A-beta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008; 7: 779–86.
29. LeBars P, Katz M, Berman N et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997; 278: 1327–32.
30. Loef M, Walach H. Fruit, vegetables and prevention of cognitive decline or dementia: a systematic review of cohort studies. J Nutr Health Aging 2012; 16 (7): 626–30.
31. Lovestone S, Davis D, Webster M et al. Lithium reduces tau phosphorylation: effects in living cells and in neurons at therapeutic concentrations. Biol Psychiatry 1999; 45: 995–1003.
32. Martin B, Szekely C, Brandt J et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 2008; 65 (7): 896–905.
33. Napryeyenko O, Borzenko I. GINDEM-NP Study Group. Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung 2007; 57 (1): 4–11.
34. Nurk E, Drevon C, Refsum H et al. Cognitive performance among the elderly and dietary fish intake: the Hordaland Health Study. Am J Clin Nutr 2007; 86: 1470–8.
35. Panza F, Frisardi V, Solfrizzi V et al. Immunotherapy for Alzheimer's disease: from anti-и-amyloid to tau-based immunization strategies. Immunotherapy 2012; 4 (2): 213–38.
36. Petersen R, Smith G, Waring S et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303–8.
37. Petersen R, Thomas R, Grundman M et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352 (23): 2379–88.
38. Ravaglia G, Forti P, Lucicesare A et al. Physical activity and dementia risk in the elderly: findings a prospective Italian study. Neurology 2008; 70: 1786–94.
39. Shepherd J, Blauw G, Murphy M et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623–30.
40. Sparks D, Kryscio R, Sabbagh M et al. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res 2008; 5: 416–21.
41. Vellas B, Coley N, Ousset P et al. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 2012; 10: 851–9.
42. Weinmann S, Roll S, Schwarzbach C et al. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr 2010; 10: 14.
43. Weinstein А, Barton C, Ross L et al. Treatment Practices of Mild Cognitive Impairment in California Alzheimer's Disease Centers. J Am Geriatr Soc 2009; 57 (4): 686–90.
44. Wilcock G, Black S, Hendrix S et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 2008; 7: 483–93.
45. Willis S, Tennstedt S, Marsiske M et al. Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA 2006; 296: 2805–14.
46. Winblad B, Fioravanti M, Dolezal T et al. Therapeutic use of nicergoline. Clin Drug Investig 2008; 28 (9): 533–52.

А.Ю.Емелин 

ФГКВО УВПО Военно-медицинская академия им. С.М.Кирова, Санкт-Петербург